Bio-Rad Laboratories (BIO) vs Revvity (RVTY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Revvity (RVTY) has outperformed Bio-Rad Laboratories (BIO) over the past year, gaining 68.4% versus a gain of 24.1%. Over five years, RVTY leads with a -9.6% price change compared with -49.0% for BIO. Revvity is the larger company by market cap ($16.74 billion vs $9.60 billion), about 1.7 times the size.
On valuation, Revvity trades at a lower forward P/E (25.5x vs 36.2x for Bio-Rad Laboratories). Revvity pays a dividend yielding 0.19%, while Bio-Rad Laboratories does not currently pay one. Bio-Rad Laboratories converts more of its revenue into profit, with a net margin of 29.4% versus 8.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIO | RVTY |
|---|---|---|
| Share price | $358.96 | $150.02 |
| Market cap | $9.60B | $16.74B |
| 1-day change | -2.44% | -2.33% |
| YTD return | +21.43% | +58.76% |
| 1-year return | +24.08% | +68.44% |
| 5-year return | -49.00% | -9.55% |
| P/E ratio (TTM) | 45.49 | 71.78 |
| Forward P/E | 36.20 | 25.45 |
| EPS (TTM) | $7.89 | $2.09 |
| Dividend yield | 0.00% | 0.19% |
| Annual dividend | $0.00 | $0.28 |
| Revenue (latest FY) | $2.58B | $2.86B |
| Revenue growth (YoY) | +0.65% | +3.67% |
| Net income (latest FY) | $759.90M | $241.20M |
| Gross margin | 51.87% | — |
| Operating margin | 1.83% | 12.49% |
| Net margin | 29.42% | 8.45% |
| 52-week high | $396.23 | $166.25 |
| 52-week low | $236.73 | $81.22 |
| Distance from 52-week high | -9.41% | -9.76% |
| Analyst consensus | hold | buy |
| Avg. price target upside | -8.53% | -9.43% |
| Average volume | 276.93K | 1.79M |
| Shares outstanding | 21.68M | 111.59M |
| Employees | 7,450 | 11,000 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RVTY has outperformed BIO by 44.4 percentage points over the past year.
- Revvity trades at a higher earnings multiple (71.8x vs 45.5x trailing P/E).
- Bio-Rad Laboratories is more profitable, keeping 29.4 cents of every revenue dollar as net income versus 8.4 cents for Revvity.
About Bio-Rad Laboratories
BIO stock →Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally.
Industrials · Biotechnology: Laboratory Analytical Instruments · 7,450 employees
About Revvity
RVTY stock →Revvity, Inc. provides health sciences solutions, technologies, and services.
Industrials · Biotechnology: Laboratory Analytical Instruments · 11,000 employees
BIO vs RVTY FAQ
Which is bigger, Bio-Rad Laboratories or Revvity?
Revvity (RVTY) is larger, with a market capitalization of $16.74B compared with $9.60B for Bio-Rad Laboratories (BIO).
Which stock has performed better over the past year, BIO or RVTY?
RVTY returned +68.44% over the past 12 months, compared with +24.08% for BIO (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BIO or RVTY?
BIO has the lower trailing P/E at 45.5, versus 71.8 for RVTY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Bio-Rad Laboratories or Revvity?
Revvity pays a dividend yielding 0.19%, while Bio-Rad Laboratories does not currently pay a regular dividend.
Are Bio-Rad Laboratories and Revvity in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.